Genmab A (GMAB) Intangibles (2018 - 2026)
Genmab A's (GMAB) quarterly Intangibles came in at $8.9 billion in Q1 2026, up 409.57% YoY from $1.8 billion in Q1 2025, and down 1.92% on a QoQ basis from $9.1 billion in Q4 2025.
Genmab A (GMAB) Intangibles (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Intangibles data on file, last reported at $8.9 billion in Q1 2026.
- Quarterly Intangibles rose 409.57% year-over-year to $8.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 billion (up 409.57% YoY) and the FY2025 annual result came in at $9.1 billion, up 427.95% from the prior year.
- Intangibles declined to $8.9 billion in Q1 2026, from $9.1 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $9.1 billion in Q4 2025 to a low of $15.0 million in Q4 2023.
- A 4-year average of $3.6 billion and a median of $1.8 billion in 2025 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2024 — Intangibles soared 11420.0% — and 2026, when it jumped 409.57%.
- Tracing GMAB's Intangibles over 4 years: stood at $15.0 million in 2023, then soared by 11420.0% to $1.7 billion in 2024, then surged by 427.95% to $9.1 billion in 2025, then declined by 1.92% to $8.9 billion in 2026.
- The last three Intangibles figures came in at $8.9 billion (Q1 2026), $9.1 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 8.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.87 Bn |
| Mar 31, 2026 | 8.95 Bn |
| Dec 31, 2025 | 9.12 Bn |
| Sep 30, 2025 | 1.75 Bn |
| Jun 30, 2025 | 1.75 Bn |
| Mar 31, 2025 | 1.76 Bn |
| Dec 31, 2024 | 1.73 Bn |
| Dec 31, 2023 | 15.00 Mn |
| Sep 30, 2020 | 385.00 |
| Dec 31, 2019 | 470.00 |
| Sep 30, 2019 | 419.63 Mn |
| Dec 31, 2018 | 470.36 Mn |